Table 4.
Non-compartmental pharmacokinetic parameter estimates
| Carfilzomib Pharmacokinetic parameters summary | |||||
|---|---|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 8 | ||||
| Dose=20 mg/m2 (n=19) | Dose=27 mg/m2 (n=4) | Dose=36 mg/m2 (n=4) | Dose=45 mg/m2 (n=3) | Dose=56 mg/m2 (n=5)* | |
| Parameters | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD |
| AUCall (hr*ng/mL) | 247± 150 | 234± 71.6 | 360± 106 | 360± 34.5 | 785± 265 |
| T½ (hr) | 1.4± 1.6 | 0.7± 0.4 | 0.6± 0.4 | 1.1± 0.6 | 1.0± 0.2 |
| Cmax (ng/mL) | 559± 227 | 591± 196 | 918± 330 | 932± 73.0 | 1653± 112 |
| CL (L/hr/m2) | 95.9± 33.9 | 123± 35.6 | 107± 30.2 | 126± 12.6 | 78.4± 27.4 |
| Vss (L/m2) | 23.8± 37.4 | 16.3± 7.2 | 14.5± 9.6 | 11.6± 1.1 | 11.0± 4.7 |
*
Data from one patient is excluded due to significantly higher concentrations measured in samples from that patient compared to the other 5 patients.
AUCall: area under the observed plasma concentration-time curve
T½: half-life
hr: hour
Cmax: maximum observed concentration
CL: clearance
Vss: volume of distribution at steady state